Current Updates on the Regulation of Beta-Secretase Movement as a Potential Restorative Focus for Management of Alzheimer's Disease

Athanasopoulos, D.; Karagiannis, G.; Tsolaki, M. Recent findings in alzheimer disease and nutrition focusing on epigenetics. Adv. Nutr., 2016, 7(5), 917-927.
[http://dx.doi.org/10.3945/an.116.012229] [PMID: 27633107]

Cummings, J.L.; Isaacson, R.S.; Schmitt, F.A.; Velting, D.M. A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann. Clin. Transl. Neurol., 2015, 2(3), 307-323.
[http://dx.doi.org/10.1002/acn3.166] [PMID: 25815358]

Ahmad, S.S.; Akhtar, S.; Jamal, Q.M.; Rizvi, S.M.; Kamal, M.A.; Khan, M.K.; Siddiqui, M.H.; Siddiqui, M.H. Multiple targets for the management of alzheimer’s disease. CNS Neurol. Disord. Drug Targets, 2016, 15(10), 1279-1289.
[http://dx.doi.org/10.2174/1871527315666161003165855] [PMID: 27712576]

Aprahamian, I.; Stella, F.; Forlenza, O.V. New treatment strategies for Alzheimer’s disease: is there a hope? Indian J. Med. Res., 2013, 138(4), 449-460.
[PMID: 24434253]

Alam, A.; Shaikh, S.; Ahmad, S.S.; Ansari, M.A.; Shakil, S.; Rizvi, S.M.; Shakil, S.; Imran, M.; Haneef, M.; Abuzenadah, A.M.; Kamal, M.A. Molecular interaction of human brain acetylcholinesterase with a natural inhibitor huperzine-B: an enzoinformatics approach. CNS Neurol. Disord. Drug Targets, 2014, 13(3), 487-490.
[http://dx.doi.org/10.2174/18715273113126660163] [PMID: 24059299]

Amoroso, N.; Diacono, D.; La Rocca, M.; Bellotti, R.; Tangaro, S. Salient networks: a novel application to study Alzheimer disease. Biomed. Eng. Online, 2018, 17(Suppl. 1), 162.
[http://dx.doi.org/10.1186/s12938-018-0566-5] [PMID: 30458801]

Cassani, R.; Estarellas, M.; San-Martin, R.; Fraga, F.J.; Falk, T.H. Systematic review on resting state EEG for alzheimer’s disease diagnosis and progression assessment. Dis. Markers, 2018, 20185174815
[http://dx.doi.org/10.1155/2018/5174815] [PMID: 30405860]

Rajmohan, R.; Reddy, P.H. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of alzheimer’s disease neurons. J. Alzheimers Dis., 2017, 57(4), 975-999.
[http://dx.doi.org/10.3233/JAD-160612] [PMID: 27567878]

Morris, G.P.; Clark, I.A.; Vissel, B. Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol., 2018, 136(5), 663-689.
[http://dx.doi.org/10.1007/s00401-018-1918-8] [PMID: 30349969]

Hu, X.; Hicks, C.W.; He, W.; Wong, P.; Macklin, W.B.; Trapp, B.D.; Yan, R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci., 2006, 9(12), 1520-1525.
[http://dx.doi.org/10.1038/nn1797] [PMID: 17099708]

Sauder, J.M.; Arthur, J.W.; Dunbrack, R.L., Jr Modeling of substrate specificity of the Alzheimer’s disease amyloid precursor protein beta-secretase. J. Mol. Biol., 2000, 300(2), 241-248.
[http://dx.doi.org/10.1006/jmbi.2000.3860] [PMID: 10873463]

Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A.K.; Zhang, X.C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science, 2000, 290(5489), 150-153.
[http://dx.doi.org/10.1126/science.290.5489.150] [PMID: 11021803]

Maillard, M.C.; Hom, R.K.; Benson, T.E.; Moon, J.B.; Mamo, S.; Bienkowski, M.; Tomasselli, A.G.; Woods, D.D.; Prince, D.B.; Paddock, D.J.; Emmons, T.L.; Tucker, J.A.; Dappen, M.S.; Brogley, L.; Thorsett, E.D.; Jewett, N.; Sinha, S.; John, V. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J. Med. Chem., 2007, 50(4), 776-781.
[http://dx.doi.org/10.1021/jm061242y] [PMID: 17300163]

Descamps, O.; Spilman, P.; Zhang, Q.; Libeu, C.P.; Poksay, K.; Gorostiza, O.; Campagna, J.; Jagodzinska, B.; Bredesen, D.E.; John, V. AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer’s disease. J. Alzheimers Dis., 2013, 37(2), 343-355.
[http://dx.doi.org/10.3233/JAD-130578] [PMID: 23948888]

Lee, J.; Samson, A.A.S.; Song, J.M. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer’s disease. Anal. Chim. Acta, 2018, 1022, 89-95.
[http://dx.doi.org/10.1016/j.aca.2018.03.033] [PMID: 29729742]

Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300(5618), 486-489.
[http://dx.doi.org/10.1126/science.1079469] [PMID: 12702875]

Walsh, D.M.; Klyubin, I.; Shankar, G.M.; Townsend, M.; Fadeeva, J.V.; Betts, V.; Podlisny, M.B.; Cleary, J.P.; Ashe, K.H.; Rowan, M.J.; Selkoe, D.J. The role of cell-derived oligomers of Abeta in Alzheimer’s disease and avenues for therapeutic intervention. Biochem. Soc. Trans., 2005, 33(Pt 5), 1087-1090.
[http://dx.doi.org/10.1042/BST0331087] [PMID: 16246051]

Lesné, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 2006, 440(7082), 352-357.
[http://dx.doi.org/10.1038/nature04533] [PMID: 16541076]

Deane, R.; Bell, R.D.; Sagare, A.; Zlokovic, B.V. Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets, 2009, 8(1), 16-30.
[http://dx.doi.org/10.2174/187152709787601867] [PMID: 19275634]

Hone, E.; Martins, I.J.; Fonte, J.; Martins, R.N. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J. Alzheimers Dis., 2003, 5(1), 1-8.
[http://dx.doi.org/10.3233/JAD-2003-5101] [PMID: 12590160]

Ghiso, J.; Shayo, M.; Calero, M.; Ng, D.; Tomidokoro, Y.; Gandy, S.; Rostagno, A.; Frangione, B. Systemic catabolism of alzheimer’s Abeta40 and Abeta42. J. Biol. Chem., 2004, 279(44), 45897-45908.
[http://dx.doi.org/10.1074/jbc.M407668200] [PMID: 15322125]

Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B.L.; Lieberburg, I.; Koo, E.H.; Schenk, D.; Teplow, D.B.; Selkoe, D.J. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359(6393), 322-325.
[http://dx.doi.org/10.1038/359322a0] [PMID: 1383826]

Seubert, P.; Oltersdorf, T.; Lee, M.G.; Barbour, R.; Blomquist, C.; Davis, D.L.; Bryant, K.; Fritz, L.C.; Galasko, D.; Thal, L.J.; Lieberburg, I.; Schenk, D.B. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature, 1993, 361(6409), 260-263.
[http://dx.doi.org/10.1038/361260a0] [PMID: 7678698]

Zhao, J.; Paganini, L.; Mucke, L.; Gordon, M.; Refolo, L.; Carman, M.; Sinha, S.; Oltersdorf, T.; Lieberburg, I.; McConlogue, L. β-secretase processing of the β-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. J. Biol. Chem., 1996, 271(49), 31407-31411.
[http://dx.doi.org/10.1074/jbc.271.49.31407] [PMID: 8940150]

Marwarha, G.; Claycombe-Larson, K.; Lund, J.; Ghribi, O. Palmitate-Induced SREBP1 expression and activation underlies the increased BACE 1 activity and amyloid beta genesis. Mol. Neurobiol., 2019, 56(7), 5256-5269.
[http://dx.doi.org/10.1007/s12035-018-1451-8] [PMID: 3056941]

Haass, C.; Hung, A.Y.; Schlossmacher, M.G.; Teplow, D.B.; Selkoe, D.J. β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem., 1993, 268(5), 3021-3024.
[PMID: 8428976]

Haass, C.; Capell, A.; Citron, M.; Teplow, D.B.; Selkoe, D.J. The vacuolar H(+)-ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type beta-amyloid precursor protein. J. Biol. Chem., 1995, 270(11), 6186-6192.
[http://dx.doi.org/10.1074/jbc.270.11.6186] [PMID: 7890753]

Knops, J.; Suomensaari, S.; Lee, M.; McConlogue, L.; Seubert, P.; Sinha, S. Cell-type and amyloid precursor protein-type specific inhibition of A β release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. J. Biol. Chem., 1995, 270(6), 2419-2422.
[http://dx.doi.org/10.1074/jbc.270.6.2419] [PMID: 7852298]

Koo, E.H.; Squazzo, S.L. Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem., 1994, 269(26), 17386-17389.
[PMID: 8021238]

Haass, C.; Lemere, C.A.; Capell, A.; Citron, M.; Seubert, P.; Schenk, D.; Lannfelt, L.; Selkoe, D.J. The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat. Med., 1995, 1(12), 1291-1296.
[http://dx.doi.org/10.1038/nm1295-1291] [PMID: 7489411]

Kao, S.C.; Krichevsky, A.M.; Kosik, K.S.; Tsai, L.H. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem., 2004, 279(3), 1942-1949.
[http://dx.doi.org/10.1074/jbc.M309219200] [PMID: 14600149]

Ohno, M.; Sametsky, E.A.; Younkin, L.H.; Oakley, H.; Younkin, S.G.; Citron, M.; Vassar, R.; Disterhoft, J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron, 2004, 41(1), 27-33.
[http://dx.doi.org/10.1016/S0896-6273(03)00810-9] [PMID: 14715132]

Hussain, I.; Hawkins, J.; Harrison, D.; Hille, C.; Wayne, G.; Cutler, L.; Buck, T.; Walter, D.; Demont, E.; Howes, C.; Naylor, A.; Jeffrey, P.; Gonzalez, M.I.; Dingwall, C.; Michel, A.; Redshaw, S.; Davis, J.B. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J. Neurochem., 2007, 100(3), 802-809.
[http://dx.doi.org/10.1111/j.1471-4159.2006.04260.x] [PMID: 17156133]

Arbor, S.C.; LaFontaine, M.; Cumbay, M. Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. Yale J. Biol. Med., 2016, 89(1), 5-21.
[PMID: 27505013]

Dulin, F.; Léveillé, F.; Ortega, J.B.; Mornon, J.P.; Buisson, A.; Callebaut, I.; Colloc’h, N. P3 peptide, a truncated form of A β devoid of synaptotoxic effect, does not assemble into soluble oligomers. FEBS Lett., 2008, 582(13), 1865-1870.
[http://dx.doi.org/10.1016/j.febslet.2008.05.002] [PMID: 18474239]

Cook, D.G.; Forman, M.S.; Sung, J.C.; Leight, S.; Kolson, D.L.; Iwatsubo, T.; Lee, V.M.; Doms, R.W. Alzheimer’s A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med., 1997, 3(9), 1021-1023.
[http://dx.doi.org/10.1038/nm0997-1021] [PMID: 9288730]

Jankowsky, J.L.; Fadale, D.J.; Anderson, J.; Xu, G.M.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Lee, M.K.; Younkin, L.H.; Wagner, S.L.; Younkin, S.G.; Borchelt, D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet., 2004, 13(2), 159-170.
[http://dx.doi.org/10.1093/hmg/ddh019] [PMID: 14645205]

Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
[http://dx.doi.org/10.1016/S0140-6736(08)61075-2] [PMID: 18640458]

Laird, F.M.; Cai, H.; Savonenko, A.V.; Farah, M.H.; He, K.; Melnikova, T.; Wen, H.; Chiang, H.C.; Xu, G.; Koliatsos, V.E.; Borchelt, D.R.; Price, D.L.; Lee, H.K.; Wong, P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci., 2005, 25(50), 11693-11709.
[http://dx.doi.org/10.1523/JNEUROSCI.2766-05.2005] [PMID: 16354928]

Marwarha, G.; Raza, S.; Meiers, C.; Ghribi, O. Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim. Biophys. Acta, 2014, 1842(9), 1587-1595.
[http://dx.doi.org/10.1016/j.bbadis.2014.05.015] [PMID: 24874077]

O'Connor, T.; Sadleir, K.R.; Maus, E.; Velliquette, R.A.; Zhao, J.; Cole, S.L.; Eimer, W.A.; Hitt, B.; Bembinster, L.A.; Lammich, S.; Lichtenthaler, S.F.; Hebert, S.S.; De Strooper, B.; Haass, C.; Bennett, D.A.; Vassar, R. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron, 2008, 60(6), 988-1009.
[http://dx.doi.org/10.1016/j.neuron.2008.10.047] [PMID: 19109907]

Guglielmotto, M.; Aragno, M.; Autelli, R.; Giliberto, L.; Novo, E.; Colombatto, S.; Danni, O.; Parola, M.; Smith, M.A.; Perry, G.; Tamagno, E.; Tabaton, M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem., 2009, 108(4), 1045-1056.
[http://dx.doi.org/10.1111/j.1471-4159.2008.05858.x] [PMID: 19196431]

Wolfe, M.S. Inhibition and modulation of gamma-secretase for Alzheimer’s disease. Neurotherapeutics, 2008, 5(3), 391-398.
[http://dx.doi.org/10.1016/j.nurt.2008.05.010] [PMID: 18625450]

Glenner, G.G.; Wong, C.W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem. Biophys. Res. Commun., 2012, 425(3), 534-539.
[http://dx.doi.org/10.1016/j.bbrc.2012.08.020] [PMID: 22925670]

Haass, C.; Koo, E.H.; Mellon, A.; Hung, A.Y.; Selkoe, D.J. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature, 1992, 357(6378), 500-503.
[http://dx.doi.org/10.1038/357500a0] [PMID: 1608449]

Amaro, M.; Šachl, R.; Aydogan, G.; Mikhalyov, I.I.; Vacha, R.; Hof, M. GM1 ganglioside inhibits beta-amyloid oligomerization induced by sphingomyelin. Angew. Chem. Int. Ed. Engl., 2016, 55(32), 9411-9415.
[http://dx.doi.org/10.1002/anie.201603178] [PMID: 27295499]

Canevari, L.; Abramov, A.Y.; Duchen, M.R. Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem. Res., 2004, 29(3), 637-650.
[http://dx.doi.org/10.1023/B:NERE.0000014834.06405.af] [PMID: 15038611]

Gomes, B.A.Q.; Silva, J.P.B.; Romeiro, C.F.R.; Dos Santos, S.M.; Rodrigues, C.A.; Goncalves, P.R.; Sakai, J.T.; Mendes, P.F.S.; Varela, E.L.P.; Monteiro, M.C. Neuroprotective mechanisms of resveratrol in alzheimer’s disease: Role of SIRT1. Oxid. Med. Cell. Longev., 2018, 20188152373
[http://dx.doi.org/10.1155/2018/8152373] [PMID: 30510627]

Turner, A.J.; Tanzawa, K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J., 1997, 11(5), 355-364.
[http://dx.doi.org/10.1096/fasebj.11.5.9141502] [PMID: 9141502]

Angus, R.M.; Millar, E.A.; Chalmers, G.W.; Thomson, N.C. Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP). Thorax, 1996, 51(1), 71-74.
[http://dx.doi.org/10.1136/thx.51.1.71] [PMID: 8658373]

Strittmatter, W.J.; Saunders, A.M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G.S.; Roses, A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1993, 90(5), 1977-1981.
[http://dx.doi.org/10.1073/pnas.90.5.1977] [PMID: 8446617]

Shibata, M.; Yamada, S.; Kumar, S.R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.M.; Miller, C.A.; Strickland, D.K.; Ghiso, J.; Zlokovic, B.V. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 2000, 106(12), 1489-1499.
[http://dx.doi.org/10.1172/JCI10498] [PMID: 11120756]

Deane, R.; Wu, Z.; Sagare, A.; Davis, J.; Du Yan, S.; Hamm, K.; Xu, F.; Parisi, M.; LaRue, B.; Hu, H.W.; Spijkers, P.; Guo, H.; Song, X.; Lenting, P.J.; Van Nostrand, W.E.; Zlokovic, B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 2004, 43(3), 333-344.
[http://dx.doi.org/10.1016/j.neuron.2004.07.017] [PMID: 15294142]

Mackic, J.B.; Stins, M.; McComb, J.G.; Calero, M.; Ghiso, J.; Kim, K.S.; Yan, S.D.; Stern, D.; Schmidt, A.M.; Frangione, B.; Zlokovic, B.V. Human blood-brain barrier receptors for Alzheimer’s amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest., 1998, 102(4), 734-743.
[http://dx.doi.org/10.1172/JCI2029] [PMID: 9710442]

Stern, D.M.; Yan, S.D.; Yan, S.F.; Schmidt, A.M. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev., 2002, 1(1), 1-15.
[http://dx.doi.org/10.1016/S0047-6374(01)00366-9] [PMID: 12039445]

LaRue, B.; Hogg, E.; Sagare, A.; Jovanovic, S.; Maness, L.; Maurer, C.; Deane, R.; Zlokovic, B.V. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J. Neurosci. Methods, 2004, 138(1-2), 233-242.
[http://dx.doi.org/10.1016/j.jneumeth.2004.04.026] [PMID: 15325132]

Shibata, M1.; Yamada, S.; Kumar, S.R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.M.; Miller, C.A.; Strickland, D.K.; Ghiso, J.; Zlokovic, B.V. Clearance of alzheimer’s amyloid-beta1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 2000, 106, 1489-1499.

Deane, R.; Wu, Z.; Sagare, A.; Davis, J.; Du Yan, S.; Hamm, K.; Xu, F.; Parisi, M.; LaRue, B.; Hu, H.W.; Spijkers, P.; Guo, H.; Song, X.; Lenting, P.J.; Van Nostrand, W.E.; Zlokovic, B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 2004, 43(3), 333-344.
[http://dx.doi.org/10.1016/j.neuron.2004.07.017] [PMID: 15294142]

Aksenov, M.Yu. Aksenova, M.V.; Harris, M.E.; Hensley, K.; Butterfield, D.A.; Carney, J.M. Enhancement of beta-amyloid peptide A beta(1-40)-mediated neurotoxicity by glutamine synthetase. J. Neurochem., 1995, 65(4), 1899-1902.
[http://dx.doi.org/10.1046/j.1471-4159.1995.65041899.x] [PMID: 7561891]

Yatin, S.M.; Yatin, M.; Aulick, T.; Ain, K.B.; Butterfield, D.A. Alzheimer’s amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci. Lett., 1999, 263(1), 17-20.
[http://dx.doi.org/10.1016/S0304-3940(99)00101-9] [PMID: 10218900]

Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Bulter, T.; Kang, D.E.; Marquez-Sterling, N.; Golde, T.E.; Koo, E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414(6860), 212-216.
[http://dx.doi.org/10.1038/35102591] [PMID: 11700559]

Neniskyte, U.; Neher, J.J.; Brown, G.C. Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia. J. Biol. Chem., 2011, 286(46), 39904-39913.
[http://dx.doi.org/10.1074/jbc.M111.267583] [PMID: 21903584]

Raghavan, N.; Tosto, G. Genetics of alzheimer’s disease: The Importance of polygenic and epistatic components. Curr. Neurol. Neurosci. Rep., 2017, 17(10), 78.
[http://dx.doi.org/10.1007/s11910-017-0787-1] [PMID: 28825204]

Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3(8), 711-715.
[http://dx.doi.org/10.1038/nrd1470] [PMID: 15286737]

Waring, S.C.; Rosenberg, R.N. Genome-wide association studies in Alzheimer disease. Arch. Neurol., 2008, 65(3), 329-334.
[http://dx.doi.org/10.1001/archneur.65.3.329] [PMID: 18332245]

Mahley, R.W.; Weisgraber, K.H.; Huang, Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc. Natl. Acad. Sci. USA, 2006, 103(15), 5644-5651.
[http://dx.doi.org/10.1073/pnas.0600549103] [PMID: 16567625]

Jonsson, T.; Stefansson, H.; Steinberg, S.; Jonsdottir, I.; Jonsson, P.V.; Snaedal, J.; Bjornsson, S.; Huttenlocher, J.; Levey, A.I.; Lah, J.J.; Rujescu, D.; Hampel, H.; Giegling, I.; Andreassen, O.A.; Engedal, K.; Ulstein, I.; Djurovic, S.; Ibrahim-Verbaas, C.; Hofman, A.; Ikram, M.A.; van Duijn, C.M.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med., 2013, 368(2), 107-116.
[http://dx.doi.org/10.1056/NEJMoa1211103] [PMID: 23150908]

Lambert, J.C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; DeStafano, A.L.; Bis, J.C.; Beecham, G.W.; Grenier-Boley, B.; Russo, G.; Thorton-Wells, T.A.; Jones, N.; Smith, A.V.; Chouraki, V.; Thomas, C.; Ikram, M.A.; Zelenika, D.; Vardarajan, B.N.; Kamatani, Y.; Lin, C.F.; Gerrish, A.; Schmidt, H.; Kunkle, B.; Dunstan, M.L.; Ruiz, A.; Bihoreau, M.T.; Choi, S.H.; Reitz, C.; Pasquier, F.; Cruchaga, C.; Craig, D.; Amin, N.; Berr, C.; Lopez, O.L.; De Jager, P.L.; Deramecourt, V.; Johnston, J.A.; Evans, D.; Lovestone, S.; Letenneur, L.; Moron, F.J.; Rubinsztein, D.C.; Eiriksdottir, G.; Sleegers, K.; Goate, A.M.; Fiévet, N.; Huentelman, M.W.; Gill, M.; Brown, K.; Kamboh, M.I.; Keller, L.; Barberger-Gateau, P.; McGuiness, B.; Larson, E.B.; Green, R.; Myers, A.J.; Dufouil, C.; Todd, S.; Wallon, D.; Love, S.; Rogaeva, E.; Gallacher, J.; St George-Hyslop, P.; Clarimon, J.; Lleo, A.; Bayer, A.; Tsuang, D.W.; Yu, L.; Tsolaki, M.; Bossù, P.; Spalletta, G.; Proitsi, P.; Collinge, J.; Sorbi, S.; Sanchez-Garcia, F.; Fox, N.C.; Hardy, J.; Deniz Naranjo, M.C.; Bosco, P.; Clarke, R.; Brayne, C.; Galimberti, D.; Mancuso, M.; Matthews, F.; Moebus, S.; Mecocci, P.; Del Zompo, M.; Maier, W.; Hampel, H.; Pilotto, A.; Bullido, M.; Panza, F.; Caffarra, P.; Nacmias, B.; Gilbert, J.R.; Mayhaus, M.; Lannefelt, L.; Hakonarson, H.; Pichler, S.; Carrasquillo, M.M.; Ingelsson, M.; Beekly, D.; Alvarez, V.; Zou, F.; Valladares, O.; Younkin, S.G.; Coto, E.; Hamilton-Nelson, K.L.; Gu, W.; Razquin, C.; Pastor, P.; Mateo, I.; Owen, M.J.; Faber, K.M.; Jonsson, P.V.; Combarros, O.; O’Donovan, M.C.; Cantwell, L.B.; Soininen, H.; Blacker, D.; Mead, S.; Mosley, T.H., Jr; Bennett, D.A.; Harris, T.B.; Fratiglioni, L.; Holmes, C.; de Bruijn, R.F.; Passmore, P.; Montine, T.J.; Bettens, K.; Rotter, J.I.; Brice, A.; Morgan, K.; Foroud, T.M.; Kukull, W.A.; Hannequin, D.; Powell, J.F.; Nalls, M.A.; Ritchie, K.; Lunetta, K.L.; Kauwe, J.S.; Boerwinkle, E.; Riemenschneider, M.; Boada, M.; Hiltuenen, M.; Martin, E.R.; Schmidt, R.; Rujescu, D.; Wang, L.S.; Dartigues, J.F.; Mayeux, R.; Tzourio, C.; Hofman, A.; Nöthen, M.M.; Graff, C.; Psaty, B.M.; Jones, L.; Haines, J.L.; Holmans, P.A.; Lathrop, M.; Pericak-Vance, M.A.; Launer, L.J.; Farrer, L.A.; van Duijn, C.M.; Van Broeckhoven, C.; Moskvina, V.; Seshadri, S.; Williams, J.; Schellenberg, G.D.; Amouyel, P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet., 2013, 45(12), 1452-1458.
[http://dx.doi.org/10.1038/ng.2802] [PMID: 24162737]

Ankarcrona, M.; Winblad, B.; Monteiro, C.; Fearns, C.; Powers, E.T.; Johansson, J.; Westermark, G.T.; Presto, J.; Ericzon, B.G.; Kelly, J.W. Current and future treatment of amyloid diseases. J. Intern. Med., 2016, 280(2), 177-202.
[http://dx.doi.org/10.1111/joim.12506] [PMID: 27165517]

Chen, G.F.; Xu, T.H.; Yan, Y.; Zhou, Y.R.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin., 2017, 38(9), 1205-1235.
[http://dx.doi.org/10.1038/aps.2017.28] [PMID: 28713158]

Godyń, J.; Jończyk, J.; Panek, D.; Malawska, B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol. Rep., 2016, 68(1), 127-138.
[http://dx.doi.org/10.1016/j.pharep.2015.07.006] [PMID: 26721364]

Frisardi, V.; Solfrizzi, V.; Imbimbo, P.B.; Capurso, C.; D’Introno, A.; Colacicco, A.M.; Vendemiale, G.; Seripa, D.; Pilotto, A.; Capurso, A.; Panza, F. Towards disease-modifying treatment of Alzheimer’s disease: drugs targeting beta-amyloid. Curr. Alzheimer Res., 2010, 7(1), 40-55.
[http://dx.doi.org/10.2174/156720510790274400] [PMID: 19939231]

Eketjäll, S.; Janson, J.; Kaspersson, K.; Bogstedt, A.; Jeppsson, F.; Fälting, J.; Haeberlein, S.B.; Kugler, A.R.; Alexander, R.C.; Cebers, G. AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J. Alzheimers Dis., 2016, 50(4), 1109-1123.
[http://dx.doi.org/10.3233/JAD-150834] [PMID: 26890753]

Molecule of the month. Semagacestat. Drug News Perspect., 2008, 21(7), 390.
[PMID: 19259551]

Poli, G.; Corda, E.; Lucchini, B.; Puricelli, M.; Martino, P.A.; Dall’ara, P.; Villetti, G.; Bareggi, S.R.; Corona, C.; Vallino Costassa, E.; Gazzuola, P.; Iulini, B.; Mazza, M.; Acutis, P.; Mantegazza, P.; Casalone, C.; Imbimbo, B.P. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie. Prion, 2012, 6(1), 62-72.
[http://dx.doi.org/10.4161/pri.6.1.18317] [PMID: 22453180]

DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8850-8855.
[http://dx.doi.org/10.1073/pnas.151261398] [PMID: 11438712]

Jia, Q.; Deng, Y.; Qing, H. Potential therapeutic strategies for Alzheimer’s disease targeting or beyond β-amyloid: insights from clinical trials. BioMed Res. Int., 2014, 2014837157
[http://dx.doi.org/10.1155/2014/837157] [PMID: 25136630]

Grüninger, F. Invited review: Drug development for tauopathies. Neuropathol. Appl. Neurobiol., 2015, 41(1), 81-96.
[http://dx.doi.org/10.1111/nan.12192] [PMID: 25354646]

Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E.B.; Xie, S.X.; Joyce, S.; Li, C.; Toleikis, P.M.; Lee, V.M.; Trojanowski, J.Q. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA, 2005, 102(1), 227-231.
[http://dx.doi.org/10.1073/pnas.0406361102] [PMID: 15615853]

Mueller-Steiner, S.; Zhou, Y.; Arai, H.; Roberson, E.D.; Sun, B.; Chen, J.; Wang, X.; Yu, G.; Esposito, L.; Mucke, L.; Gan, L. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron, 2006, 51(6), 703-714.
[http://dx.doi.org/10.1016/j.neuron.2006.07.027] [PMID: 16982417]

Avramopoulos, D. Genetics of Alzheimer’s disease: recent advances. Genome Med., 2009, 1(3), 34.
[http://dx.doi.org/10.1186/gm34] [PMID: 19341505]

Huang, S.M.; Mouri, A.; Kokubo, H.; Nakajima, R.; Suemoto, T.; Higuchi, M.; Staufenbiel, M.; Noda, Y.; Yamaguchi, H.; Nabeshima, T.; Saido, T.C.; Iwata, N. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem., 2006, 281(26), 17941-17951.
[http://dx.doi.org/10.1074/jbc.M601372200] [PMID: 16636059]

Ohyagi, Y. [A drug targeting intracellular amyloid-β and oxidative stress: apomorphine] Rinsho Shinkeigaku, 2011, 51(11), 884-887.
[http://dx.doi.org/10.5692/clinicalneurol.51.884] [PMID: 22277403]

Granic, I.; Nyakas, C.; Luiten, P.G.; Eisel, U.L.; Halmy, L.G.; Gross, G.; Schoemaker, H.; Möller, A.; Nimmrich, V. Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology, 2010, 59(4-5), 334-342.
[http://dx.doi.org/10.1016/j.neuropharm.2010.07.013] [PMID: 20650285]

Zhao, W.; Wang, J.; Ho, L.; Ono, K.; Teplow, D.B.; Pasinetti, G.M. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J. Alzheimers Dis., 2009, 16(1), 49-57.
[http://dx.doi.org/10.3233/JAD-2009-0925] [PMID: 19158421]

Rogers, S.L.; Friedhoff, L.T. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia, 1996, 7(6), 293-303.
[PMID: 8915035]

Bryson, H.M.; Benfield, P. Donepezil. Drugs Aging, 1997, 10(3), 234-239.
[http://dx.doi.org/10.2165/00002512-199710030-00007] [PMID: 9108896]

Linkins, K.W.; Lloyd, J.R.; Hjelmstad, G.O.; Strausbaugh, H.J. Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigmine. Pharmacoeconomics, 2000, 18(6), 609-612.
[http://dx.doi.org/10.2165/00019053-200018060-00007] [PMID: 11227398]

Woodruff-Pak, D.S.; Tobia, M.J.; Jiao, X.; Beck, K.D.; Servatius, R.J. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. Neuropsychopharmacology, 2007, 32(6), 1284-1294.
[http://dx.doi.org/10.1038/sj.npp.1301259] [PMID: 17119537]

Riepe, M.W.; Adler, G.; Ibach, B.; Tracik, F. Adding memantine to therapy with rivastigmine in patients with mild to moderate Alzheimer’s disease: Results of a 12-week pilot study. Prim. Care Companion J. Clin. Psychiatry, 2006, 8, 258-263.
[http://dx.doi.org/10.4088/PCC.v08n0501] [PMID: 17235381]